# Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G

Source: https://onco.cc/trials/nct04613596/  
OnCo record `nct04613596` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Adagrasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Mirati Therapeutics Inc., now recruiting.

## Summary

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 is a phase 2/3 interventional study registered as NCT04613596 by Mirati Therapeutics Inc., with 626 participants planned, started 2020-12-02 and due to reach its primary completion in 2028-10-31. Interventions recorded: Adagrasib, Adagrasib, Adagrasib, Adagrasib, Pembrolizumab. Conditions listed: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04613596
- Phase: 2/3
- Setting: A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
- Sponsor: Mirati Therapeutics Inc.
- Enrolled: 626

## Sources

- ClinicalTrials.gov NCT04613596: https://clinicaltrials.gov/study/NCT04613596

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct04613596.json